Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) (Journal of Clinical Oncology (2025) DOI: 10.1200/JCO-25-00166)
Academic Article
Publication Date:
2025
Short description:
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) (Journal of Clinical Oncology (2025) DOI: 10.1200/JCO-25-00166) / Sharman, J. P.; Munir, T.; Grosicki, S.; Roeker, L. E.; Burke, J. M.; Chen, C. I.; Grzasko, N.; Follows, G.; Matrai, Z.; Sanna, A.; Qiu, L.; Feng, R.; Hua, V. M.; Jurczak, W.; Ritgen, M.; Yi, S.; Bosch, F.; Coombs, C. C.; Bao, K.; Patel, V.; Liu, B.; Compte, L.; Guntur, A.; Wang, D. Y.; Hill, M.; Leow, C. C.; Ghia, P.; Barr, P. M.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - (2025). [10.1200/JCO-25-01700]
abstract:
The article by Sharman et al entitled "Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/ Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor- Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)" (Journal of Clinical Oncology 10.1200/JCO-25-00166) was published online June 06, 2025, with errors. Figure A2, Forest plot of TTNT, was duplicated for Figure A1, Forest plot of IRC-assessed PFS. This has been corrected as of July 29, 2025. We apologize for the errors.
Iris type:
1.1.5. Erratum
List of contributors:
Sharman, J. P.; Munir, T.; Grosicki, S.; Roeker, L. E.; Burke, J. M.; Chen, C. I.; Grzasko, N.; Follows, G.; Matrai, Z.; Sanna, A.; Qiu, L.; Feng, R.; Hua, V. M.; Jurczak, W.; Ritgen, M.; Yi, S.; Bosch, F.; Coombs, C. C.; Bao, K.; Patel, V.; Liu, B.; Compte, L.; Guntur, A.; Wang, D. Y.; Hill, M.; Leow, C. C.; Ghia, P.; Barr, P. M.
Published in: